Transenterix Inc. (TRXC) 3.71 $TRXC
Surgeon Performs Live Sleeve Gastrectomy Telesurgery at International Conference Using TransEnterix's New Flex Ligating Shears
Business Wire - Wed Aug 27, 6:00AM CDT
TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the broadcast of a successful sleeve gastrectomy surgery by Dr. Helmuth Billy at the 5th International Conference on Sleeve Gastrectomy to help kick off the 2014 19th World Congress of the International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO) meeting in Montreal, Canada. Dr. Billy performed the innovative surgery from across the globe at Hamad General Hospital in Doha, Qatar using TransEnterix's Flex Ligating Shears, the only fully flexible advanced energy device available that offers ligation and division with direct thermal fusion.
TransEnterix, Inc. Reports Operating Results for the Second Quarter 2014
Business Wire - Wed Aug 06, 3:05PM CDT
--Completed sale of 14.1 million shares of common stock and raised $52.5 million, net of issuance costs
TransEnterix Schedules Second Quarter 2014 Earnings Release and Conference Call for August 6, 2014
Business Wire - Wed Jul 23, 3:05PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC) announced today that it plans to release second quarter 2014 financial and operating results after the market closes on Wednesday, August 6, 2014. Todd M. Pope, Chief Executive Officer and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 4:30 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix to Ring Opening Bell at the New York Stock Exchange
Business Wire - Mon Jul 07, 3:30PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, will ring The Opening Bell(R) of the New York Stock Exchange (NYSE) on Wednesday, July 9, 2014. The company began trading as an NYSE MKT listed company on April 15, 2014.
Global Hernia Repair Devices Market 2014-2018 with B. Braun Melsungen AG, Cook Medical, Covidien, C.R. Bard & Ethicon Dominating
M2 - Tue Jul 01, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bh28nl/global_hernia) has announced the addition of the "Global Hernia Repair Devices Market 2014-2018 with B. Braun Melsungen AG, Cook Medical, Covidien, C.R. Bard & Ethicon Dominating" report to their offering. The Global Hernia Repair Devices Market will grow at a CAGR of 6.35% to 2018. There has been an increase in the adoption of tension-free repair procedures for hernias. The Lichtenstein hernioplasty is among the most common tension-free hernia repair procedures. The procedure involves using a piece of mesh to bridge the hernia and decrease the tension on the weakened abdominal wall. This procedure offers advantages such as reducing the risk of hernia recurrence, causing minimum post-operative problems, reducing the period of hospitalization, and promoting faster healing and shorter recovery time. According to the report, the Global Hernia Repair Devices market is driven by several factors, of which the increasing incidence of hernias is one of the major drivers. Inguinal hernias are among the most widely prevalent types of hernia. As a result of the growing incidence of hernias, the demand for hernia repair devices has increased over the past few years. Further, the report states that one of the major challenges faced by the market is the complications caused by mesh materials, leading to chronic infection, pain, and hernia recurrence. Key Vendors - B. Braun Melsungen AG - Cook Medical Inc. - Covidien plc - C.R. Bard Inc. - Ethicon Inc. Other Prominent Vendors - Biomerix Corp. - CooperSurgical Inc. - Insightra Medical Inc. - KARL STORZ GmbH & Co. KG - LifeCell Corp. - Olympus Corp. - Stryker Corp. - Synovis Life Technologies Inc. - TransEnterix Inc. - W.L. Gore & Associates Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/bh...bal_hernia
TransEnterix, Inc. Announces NYSE MKT Market Listing Plans and Reverse Stock Split
Business Wire - Tue Apr 01, 4:15PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has received authorization to list its common shares on the NYSE MKT. In addition, its Board of Directors has approved a 1-for-5 reverse split of its issued and outstanding shares of common stock, which became effective on March 31, 2014. Trading of the Company's common shares will reflect the reverse stock split on April 2, 2014.
TransEnterix, Inc. Files Pre-Submission Documentation with FDA Regarding its SurgiBot System
Business Wire - Mon Mar 31, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has completed a pre-submission filing with the U.S. Food and Drug Administration ("FDA"
to request additional feedback from the FDA regarding its planned 510(k) filing for the SurgiBot(TM) system, pursuant to the FDA's Pre-Submission Program.
TransEnterix, Inc. Provides Update on Investor & Analyst Event
Business Wire - Tue Mar 25, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve the experience and outcomes of minimally invasive surgery, today announced it has postponed its Investor & Analyst Event previously-scheduled for April 3, 2014 in Salt Lake City due to a scheduling conflict with senior management. The Company continues to remain on track to complete its 2014 Key Objectives as outlined in the Company's March 6, 2014 press release, including completing a pre-submission FDA filing for the SurgiBot(TM) system in the first quarter. The Company is in the process of identifying an alternative date and location for the event.
TransEnterix, Inc. Reports Operating Results for the Fourth Quarter and Full Year 2013
Business Wire - Wed Mar 05, 6:00AM CST
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve how minimally invasive surgery is performed, today announced its operating and financial results for the fourth quarter and full year 2013, as well as its 2014 key objectives.
CORRECTING and REPLACING TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 4:23PM CST
First graph, end of second sentence of release should read: ...starting at 8:00 am Eastern Time the same day. (sted ...starting at 1:00 pm Eastern Time the same day.).
TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 3:56PM CST
TransEnterix, Inc. (OTCBB: TRXC) announced today that it plans to release fourth quarter and full year 2013 financial and operating results prior to the market open on Wednesday, March 5, 2014. Todd Pope, Chief Executive Officer and Joe Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these resulting starting at 1:00 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix, Inc. to present at the RBC Capital Markets 2014 Healthcare Conference
Business Wire - Tue Feb 11, 3:32PM CST
TransEnterix, Inc. (OTCBB:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets 2014 Healthcare Conference in New York. The presentation is scheduled to take place at 2:35 pm Eastern Time on Tuesday, February 25, 2014.
TransEnterix Enters Next Phase of Development of SurgiBot(TM) System
Business Wire - Mon Jan 13, 6:00AM CST
TransEnterix, Inc. (OTCBB: TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that multiple surgeons have used SurgiBot, the company's patient-side minimally invasive robotic system, to successfully complete general surgery procedures in the porcine model. The procedures performed in the pre-clinical testing included cholecystectomy and sleeve gastrectomy.
Surgeon Performs Live Sleeve Gastrectomy Telesurgery at International Conference Using TransEnterix's New Flex Ligating Shears
Business Wire - Wed Aug 27, 6:00AM CDT
TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the broadcast of a successful sleeve gastrectomy surgery by Dr. Helmuth Billy at the 5th International Conference on Sleeve Gastrectomy to help kick off the 2014 19th World Congress of the International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO) meeting in Montreal, Canada. Dr. Billy performed the innovative surgery from across the globe at Hamad General Hospital in Doha, Qatar using TransEnterix's Flex Ligating Shears, the only fully flexible advanced energy device available that offers ligation and division with direct thermal fusion.
TransEnterix, Inc. Reports Operating Results for the Second Quarter 2014
Business Wire - Wed Aug 06, 3:05PM CDT
--Completed sale of 14.1 million shares of common stock and raised $52.5 million, net of issuance costs
TransEnterix Schedules Second Quarter 2014 Earnings Release and Conference Call for August 6, 2014
Business Wire - Wed Jul 23, 3:05PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC) announced today that it plans to release second quarter 2014 financial and operating results after the market closes on Wednesday, August 6, 2014. Todd M. Pope, Chief Executive Officer and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 4:30 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix to Ring Opening Bell at the New York Stock Exchange
Business Wire - Mon Jul 07, 3:30PM CDT
TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, will ring The Opening Bell(R) of the New York Stock Exchange (NYSE) on Wednesday, July 9, 2014. The company began trading as an NYSE MKT listed company on April 15, 2014.
Global Hernia Repair Devices Market 2014-2018 with B. Braun Melsungen AG, Cook Medical, Covidien, C.R. Bard & Ethicon Dominating
M2 - Tue Jul 01, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bh28nl/global_hernia) has announced the addition of the "Global Hernia Repair Devices Market 2014-2018 with B. Braun Melsungen AG, Cook Medical, Covidien, C.R. Bard & Ethicon Dominating" report to their offering. The Global Hernia Repair Devices Market will grow at a CAGR of 6.35% to 2018. There has been an increase in the adoption of tension-free repair procedures for hernias. The Lichtenstein hernioplasty is among the most common tension-free hernia repair procedures. The procedure involves using a piece of mesh to bridge the hernia and decrease the tension on the weakened abdominal wall. This procedure offers advantages such as reducing the risk of hernia recurrence, causing minimum post-operative problems, reducing the period of hospitalization, and promoting faster healing and shorter recovery time. According to the report, the Global Hernia Repair Devices market is driven by several factors, of which the increasing incidence of hernias is one of the major drivers. Inguinal hernias are among the most widely prevalent types of hernia. As a result of the growing incidence of hernias, the demand for hernia repair devices has increased over the past few years. Further, the report states that one of the major challenges faced by the market is the complications caused by mesh materials, leading to chronic infection, pain, and hernia recurrence. Key Vendors - B. Braun Melsungen AG - Cook Medical Inc. - Covidien plc - C.R. Bard Inc. - Ethicon Inc. Other Prominent Vendors - Biomerix Corp. - CooperSurgical Inc. - Insightra Medical Inc. - KARL STORZ GmbH & Co. KG - LifeCell Corp. - Olympus Corp. - Stryker Corp. - Synovis Life Technologies Inc. - TransEnterix Inc. - W.L. Gore & Associates Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/bh...bal_hernia
TransEnterix, Inc. Announces NYSE MKT Market Listing Plans and Reverse Stock Split
Business Wire - Tue Apr 01, 4:15PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has received authorization to list its common shares on the NYSE MKT. In addition, its Board of Directors has approved a 1-for-5 reverse split of its issued and outstanding shares of common stock, which became effective on March 31, 2014. Trading of the Company's common shares will reflect the reverse stock split on April 2, 2014.
TransEnterix, Inc. Files Pre-Submission Documentation with FDA Regarding its SurgiBot System
Business Wire - Mon Mar 31, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has completed a pre-submission filing with the U.S. Food and Drug Administration ("FDA"
to request additional feedback from the FDA regarding its planned 510(k) filing for the SurgiBot(TM) system, pursuant to the FDA's Pre-Submission Program. TransEnterix, Inc. Provides Update on Investor & Analyst Event
Business Wire - Tue Mar 25, 3:30PM CDT
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve the experience and outcomes of minimally invasive surgery, today announced it has postponed its Investor & Analyst Event previously-scheduled for April 3, 2014 in Salt Lake City due to a scheduling conflict with senior management. The Company continues to remain on track to complete its 2014 Key Objectives as outlined in the Company's March 6, 2014 press release, including completing a pre-submission FDA filing for the SurgiBot(TM) system in the first quarter. The Company is in the process of identifying an alternative date and location for the event.
TransEnterix, Inc. Reports Operating Results for the Fourth Quarter and Full Year 2013
Business Wire - Wed Mar 05, 6:00AM CST
TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve how minimally invasive surgery is performed, today announced its operating and financial results for the fourth quarter and full year 2013, as well as its 2014 key objectives.
CORRECTING and REPLACING TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 4:23PM CST
First graph, end of second sentence of release should read: ...starting at 8:00 am Eastern Time the same day. (sted ...starting at 1:00 pm Eastern Time the same day.).
TransEnterix Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 5, 2014
Business Wire - Wed Feb 26, 3:56PM CST
TransEnterix, Inc. (OTCBB: TRXC) announced today that it plans to release fourth quarter and full year 2013 financial and operating results prior to the market open on Wednesday, March 5, 2014. Todd Pope, Chief Executive Officer and Joe Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these resulting starting at 1:00 pm Eastern Time the same day. The call will be concurrently webcast.
TransEnterix, Inc. to present at the RBC Capital Markets 2014 Healthcare Conference
Business Wire - Tue Feb 11, 3:32PM CST
TransEnterix, Inc. (OTCBB:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets 2014 Healthcare Conference in New York. The presentation is scheduled to take place at 2:35 pm Eastern Time on Tuesday, February 25, 2014.
TransEnterix Enters Next Phase of Development of SurgiBot(TM) System
Business Wire - Mon Jan 13, 6:00AM CST
TransEnterix, Inc. (OTCBB: TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that multiple surgeons have used SurgiBot, the company's patient-side minimally invasive robotic system, to successfully complete general surgery procedures in the porcine model. The procedures performed in the pre-clinical testing included cholecystectomy and sleeve gastrectomy.
